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Abstract
Background: Rotavirus was the leading cause of acute gastroenteritis (AGE) in infants and young children prior to
the introduction of routine vaccination. Since 2006 there have been two licensed vaccines available; with successful
clinical trials leading the World Health Organization to recommend rotavirus vaccination for all children worldwide.
In order to inform immunisation policy we have conducted a systematic review and meta-analysis of observation
studies to assess population effectiveness against acute gastroenteritis.
Methods: We systematically searched PubMed, Medline, Web of Science, Cinhal and Academic Search Premier and
grey literature sources for studies published between January 2006 and April 2014. Studies were eligible for
inclusion if they were observational measuring population effectiveness of rotavirus vaccination against health care
attendances for rotavirus gastroenteritis or AGE. To evaluate study quality we use used the Newcastle-Ottawa Scale
for non-randomised studies, categorising studies by risk of bias. Publication bias was assessed using funnel plots. If
two or more studies reported a measure of vaccine effectiveness (VE), we conducted a random effects meta-
analysis. We stratified analyses by World Bank country income level and used study quality in sensitivity analyses.
Results: We identified 30 studies, 19 were from high-income countries and 11 from middle-income countries.
Vaccine effectiveness against hospitalization for laboratory confirmed rotavirus gastroenteritis was highest in high-
income countries (89% VE; 95% CI 84-92%) compared to middle-income countries (74% VE; 95% CI 67-80%). Vaccine
effectiveness was higher for those receiving the complete vaccine schedule (81% VE; 95% CI 75-86%) compared to
partial schedule (62% VE; 95% CI 55-69%). Two studies from high-income countries measured VE against
community consultations for AGE with a pooled estimate of 40% (95% CI 13-58%; 2 studies).
Conclusions: We found strong evidence to further support the continued use of rotavirus vaccines. Vaccine
effectiveness was similar to that reported in clinical trials for both high and middle-income countries. There is
limited data from Low income settings at present. There was lower effectiveness against milder disease. Further
studies, should continue to report effectiveness against AGE and less-severe rotavirus disease because as evidenced
by pre-vaccine introduction studies this is likely to contribute the greatest burden on healthcare resources,
particularly in high-income countries.
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Background
Prior to the introduction of rotavirus vaccine into
childhood immunisation schedules, rotavirus was the
most common cause of severe gastroenteritis in in-
fants and young children. Thus, rotavirus gastroenter-
itis (RVGE) was estimated to be responsible for
453,000 deaths worldwide in children under 5 years
of age in 2008, with over 90% of deaths occurring in
low-income countries [1]. The global morbidity from
rotavirus infection was also substantial with pre-
vaccine introduction studies indicating that approxi-
mately 40% of diarrhoeal hospitalisations in children
were caused by rotavirus [2]. In middle and high in-
come countries without vaccination the burden of
RVGE remains substantial in infants and young chil-
dren with high rates of disease and RV the major
contributor to diarrhoea hospitalisation. In the UK
prior to vaccine introduction RVGE was estimated to
be responsible for 45% of acute gastroenteritis hos-
pital admissions, 80,000 primary care consultations
and 750,000 annual diarrhoeal episodes in children
under 5 years of age [3, 4]. In middle income coun-
tries such as, Mexico and Peru, prior to vaccine
introduction the average incidence of RVGE was 0.3
episodes per child per year in children <2 years,
resulting in significant healthcare use and mortality
[5]. Although the large majority of severe RVGE oc-
curs among young children, older children and adults
can be affected, however rotavirus infection often
causes milder symptoms or is asymptomatic in these
ages, meaning the true burden and rate of disease in-
cidence is poorly understood.
Since improvements in sanitation and hygiene are not
expected to reduce the incidence of rotavirus infection,
and treatment of RVGE is limited to rehydration ther-
apy, immunisation of infants is considered the best op-
tion for control of the global burden of rotavirus disease.
Since 2006 there have been two live-attenuated oral
rotavirus vaccines that are licensed for use globally. A
two dose monovalent vaccine (Rotarix®, GlaxoSmithKline
Biologicals, Belgium), with the first dose typically admin-
istered at between 6-8 weeks and a second dose at least 4
weeks later and a three dose pentavalent vaccine
(RotaTeq®, Merck), administered at 6-12 weeks of age
with subsequent doses at 4-10 week intervals. Rando-
mised controlled trials (RCTs) demonstrated both vac-
cines to be efficacious against severe RVGE; vaccine
efficacy of over 80% has been shown in middle and high-
income countries, whilst trials in low-income settings
have reported efficacy against severe RVGE of 40-60%
[6]. These trials led to a World Health Organisation
recommendation for universal vaccination of all children
[1, 7]. More than 90 countries have since adopted rota-
virus vaccination and the global mortality from RVGE
estimated to have fallen to 215 000 in 2013 with almost
50% of deaths occurring in four lower-income countries
[8, 9]. Currently within the European Union only nine
countries include rotavirus vaccination in their childhood
immunisation programme [10, 11].
It is now a decade since the licensing and first
introduction of rotavirus vaccination into childhood
vaccination schedule. In order to inform immunisa-
tion policy, we have conducted a systematic review
and meta-analysis of the literature on observational
studies in order to assess the population effectiveness
of the Rotarix® and RotaTeq® against rotavirus gastro-
enteritis. Effectiveness was examined by severity and
by region.
Methods
Inclusion/exclusion criteria
We included prospective or retrospective observational
studies (cohort and case-control studies) reporting the
population effectiveness of the monovalent Rotarix®
(RV1) or pentavalent RotaTeq® (RV5) against healthcare
attendance for RVGE or other acute gastroenteritis
(AGE), in countries where the vaccines are included in
the national immunisation programme or privately of-
fered through medical insurance. Studies published be-
tween January 2006 and 28th April 2014 were eligible for
inclusion. Review articles, editorials and conference ab-
stracts were included in citation checking but excluded
from final analysis. Randomised controlled trials were
also excluded.
Search strategy
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. We
systematically searched PubMed, Medline, Web of
Science, Cinhal and Academic Search Premier, OpenGrey
and the Cochrane Library databases using a well-defined
search strategy following a protocol registered on the
University of York database for Prospectively Registered
Systematic Reviews (PROSPERO: 2014:CRD42014012974).
A number of relevant organisations websites were also sys-
tematically searched, and included the World Health
Organisation, Public Health England, and Centers for
Disease Control and Prevention. We systematically
searched the literature by, pairing the terms [vacc*] and
[rotavirus] with the following key words: [immuni*],
[effect*], [ evaluation], and [efficacy].
Authors (DH and CM) replicated the search strategy
and independently screened titles and abstracts to iden-
tify full studies that were eligible for full publication re-
view. Subsequently these two authors independently
assessed the full text publications and their final inclu-
sion was based on a consensus between the reviewers
(DH, CM, KS, AT).
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Data extraction
Data extraction was autonomously carried out by
three authors (DH, AT, KS) and a collaborator (MSC)
using a pre-designed internally piloted extraction tool.
For each study the following information was ex-
tracted: Author, Year of publication, country and re-
gion of study, funding source, study period, country
vaccine coverage, study type, sample size, age of sub-
jects, type of vaccine (RV1 and / or RV5) in case and
controls groups, case definition, control definition,
number of vaccine doses, relative risks / risk ratios
(RR) or odds ratio (OR) or vaccine effectiveness (VE)
and 95% confidence intervals (95% CI) and, if applic-
able, a measure of intussusception.
Grading of selected studies
The Newcastle-Ottawa Scale (NOS) for assessing the
quality of non-randomised studies was identified as
an appropriate tool to assess study quality [12]. Case-
control and cohort-studies were assessed using the
tool by the same three researchers that carried out
data extraction. To quality assess case-control studies
the scale used: 1) adequate definition of a case and
the representativeness of cases; 2) controls selection
and case definition; 3) matching of controls or adjust-
ment for confounders in analysis; 4) ascertainment of
method of cases and controls in terms of exposure
(rotavirus vaccination) and non-response rate. To
quality assess cohort-studies the factors assessed were:
1) representativeness of the vaccinated cohort and selec-
tion of unvaccinated cohort in relation to the vaccinated;
2) ascertainment of vaccination record, confirmation of
rotavirus negative at start of study; 3) matching of ex-
posed and non-exposed in design or adjustment for con-
founders in analysis; 4) ascertainment of outcome
(rotavirus infection); 5) follow-up duration in relation to
outcome appearance (e.g. 1 year from vaccination date)
and was follow-up adequate (we defined adequate as
ascertainment of outcomes for >80% of participants).
The scale is categorised into three groups, selection,
comparability and outcome/exposure; a maximum of
nine stars can be awarded to each study. Studies scor-
ing 0 in any of the categories were classified as hav-
ing a high risk of bias, studies scoring 1 in any
categories (moderate risk of bias) and 2 or above in
all categories (low risk of bias).
Statistical analysis
We used Stata, version 14, statistical software (Stata
Corp., College Station, TX, USA) to perform all statis-
tical calculations for this meta-analysis. Meta-analyses
were conducted separately for cohort and case-control
studies. We used the study published RR for cohort
studies and OR for case-control studies and calculated
standard errors (SE) using study reported confidence in-
tervals in the formula:
SE ¼ ln Upper confidence intervalð Þ− ln Lower Confidence intervalð Þ
3:92
Where studies did not report OR or RR, authors
calculated crude OR or RR and SE using reported
numbers of cases and controls. When a study reported
both unadjusted and adjusted RRs/ORs, adjusted RRs/
ORs were included in meta-analysis and unadjusted esti-
mates excluded. Vaccine effectiveness was defined as
100 × (1 − RR) or 100 × (1 −OR). A random effects model
was used to provide pooled estimates of VE. Because of
differences in reported vaccine efficacy a decision was
taken during data extraction, for analyses to be stratified by
country income category, as defined by the World Bank
and measured using gross national income per capita
[6, 13]. Where a study had reported VE for multiple years
the estimate for mid or most recent year (if only two years)
were included in the meta-analysis. Heterogeneity was
measured using chi-squared (χ2) heterogeneity p-values
and I2 statistics. A p-value<0.1 was considered to identify
statistically significant heterogeneity rather than 0.05 due
to the small number of studies included. The percentage of
variance across studies due to heterogeneity rather than
chance was categorised as low, moderate and high using I2
values of 25-49%, 50-74% and >=75%, respectively [14].
Sensitivity analysis was conducted based on the NOS
score, excluding studies with a high or moderate risk of bias
and assessing whether a study was conducted in a country
with routine vaccination (part of recommended health
policy) or in countries where vaccination provision is pri-
vate or only available in some states. Subgroup analysis was
conducted on: number of doses (1 dose, and full doses), age
group, and vaccine type. Both number of doses and vaccine
type were identified as important analyses post-hoc. Where
studies reported had more than one type of control group
the following hierarchy was used to select estimates for use
in meta-analyses: 1) community/neighbourhood; 2) hospital
non AGE controls; hospital RV negative AGE controls.
Publication bias was checked by funnel plot asym-
metry and use of Begg’s test [15].
Results
Study characteristics
The initial search strategy identified 2,097 studies as po-
tentially relevant; of these, 30 were eligible for inclusion
in the review (Fig. 1) [16–45]. Two summary tables of
study characteristics are available in Additional file 1.
Seven studies were cohort studies and 23 were case-
control studies (Tables 1 and 2.) Nineteen were from
high-income countries and eleven were from middle in-
come countries. Seven studies declared some funding
from industry related to the rotavirus vaccines under
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study. Over a third of studies were conducted in the
USA (n=12). The majority of studies (27/30) reported on
RVGE hospitalisations and/or emergency department
(ED) attendances for AGE with a positive laboratory test
for rotavirus. A study by Mast et al., [16] measuring vac-
cine effectiveness against RVGE hospitalisation and ED
attendances included only cases with severe disease de-
fined by a Vesikari score of greater than 11 in their VE
estimate [16, 46, 47]. Two studies reported RVGE ED at-
tendances and hospitalisations combined. Five studies
included community consultations for either RVGE or
AGE [17–21], which included a range of definitions
including outpatient attendance, physician consult-
ation and telephone consultation. The study by Fontes
Vieira et al. 2011 conducted in Brazil on a community
cohort examined effectiveness of vaccination against
laboratory confirmed RVGE but did not report an
estimate of VE; a crude estimate was therefore calculated
by the authors [17]. In the majority of studies, laboratory
confirmation of RVGE followed hospitalisation, an ED
attendance or GP consultation for gastroenteritis symp-
toms such as diarrhoea. Study selection identified five
studies from countries (Spain and Israel) where routine
childhood vaccination is not available but either the
monovalent or pentavalent vaccine is available privately
and / or only in some states [18, 22, 24, 31, 42].
Controls for case-control studies were primarily hospital
controls that were admitted for AGE symptoms but with a
rotavirus negative laboratory test result. A few studies also
used community asymptomatic controls or non-AGE hos-
pital controls, such as children admitted with acute re-
spiratory infection (Additional file 1: Table S2). VE was
measured for a range of age groups across studies.
Quality of included observational studies
The quality of studies varied considerably (Table 3). It was
difficult to ascertain for most studies whether history of
disease in control subjects was considered. The majority of
studies used a combination of vaccination cards and
medical records to ascertain vaccination status. The major-
ity of studies either matched controls or adjusted for age in
the analysis as a minimum and those with community con-
trols often used an indicator of residence such as GP loca-
tion as a covariate. A high risk of bias was identified in two
out of seven cohort studies [17, 23] and two out of 23
case-control studies had a high risk of bias [24, 25].
Meta-analysis of vaccine effectiveness against
hospitalisation or combined hospitalisation and emergency
department attendance for laboratory confirmed RVGE
For this outcome measure cohort studies were too few
to conduct a meta-analysis (Table 1). We therefore,
Fig. 1 Flow chart of publications included and excluded for this review
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included 21 out of the 22 case control studies that mea-
sured vaccine effectiveness against hospitalisation or
hospitalisation and ED attendance for laboratory con-
firmed RVGE in the meta-analysis. Patel et al. 2009 was
excluded because a more recent publication Patel et al.,
2012 provided more recent estimates of effectiveness for
the same cohort [26, 27]. If studies reported more than
one age group the overall estimate for the broadest age
group was included in the meta-analysis. Studies which
reported on 0 doses vs full dose or 0 dose vs 1+ dose
Table 1 Cohort study vaccine effectiveness against hospitalisations, emergency department attendances and community
consultations for RVGE or AGE
Study Country Vaccine Age-group
(months)
Cohort
year
Vaccinated (N) Incidence among
unvaccinated (N)
Vaccine effectiveness
(95% CI)
Dose Incidence Unadjusted Adjusted
Hospitalisation for RVGE
Eberly et al. 2011 [23] USA RV1 and RV5 <60 All 1 NR 581/237660 86 (78-91) NR
1 or more 42/140213 88 (83-91) NR
2 RV1 / 3 RV5 11/NR 90 (82-95) NR
Panozzo et al. 2014* [30] USA RV1 and RV5 8-20 1 1 or more 3/68380 60/64929 NR 87 (58-96)
2 23/175890 91/91051 NR 87 (80-92)
3 22/250035 74/61218 NR 92 (87-95)
4 8/254377 13/41946 NR 90 (75-96)
Hospitalisation and ED attendance for RVGE
Wang et al. 2010 [20] USA RV5 <36 All 3 0/7700 23/5831 100 (87-100) NR
Wang, 2013 [21] USA RV5 <36 All 1 2/5019 11/3343 88 (45-99) NR
All 2 1/5886 13/4432 94 (61-100) NR
Hospitalisation and ED attendance for AGE
Wang et al. 2010 [20] USA RV5 <36 All 3 87/7700 160/5831 59 (46-69) 59 (47-68)
Wang, 2013 [21] USA RV5 <36 All 1 53/5019- 63/3343 44 (18-62) 46 (22-63)
All 2 78/5886 98/4432 40 (18-56) 39 (16-55)
Hospitalisation for AGE
Panozzo et al. 2014* [30] USA RV1 and RV5 8-20 1 1 or more 142/68378 271/64928 NR 22 (3-37)
2 413/175765 317/90882 NR 40 (30-48)
3 512/249838 300/61136 NR 56 (49-62)
4 398/254232 109/41888 NR 41 (27-53)
Community consultations for RVGE
Wang et al. 2010 [20] USA RV5 <36 All 3 1/7700 20/5831 96 (76-100) NR
Wang et al. 2013 [21] USA RV5 <36 All 1 0/5019 - 7/3343 100 (54-100) NR
All 2 4/5886 5/4432 40 (<0-88) NR
Community consultations for AGE
Fontes-Vieira et al. 2011 [17]** Brazil RV1 <12 1 2 87/100 84/100 -4 (-16 to 8) NR
2 52/100 42/100 -24 (-67 to 8) NR
Muhsen et al. 2011 [18] Israel RV1 <12 All 1 153/716 8801/18591 54 (47-60) NR
All 2 1605/6870 50 (47-52) NR
Nolan et al. 2012 [19]† USA RV5 <24 1 1 or more NR NR NR 28 (-21 to58)
1 NR NR NR 22 (-13 to 46)
2 NR NR NR 37 (-37 to 71)
Wang et al. 2010 [20] USA RV5 <36 All 3 1321/7700 1377/5831 27 (22-33) 28 (22-33)
Wang et al. 2013 [21] USA RV5 <36 All 1 651/5019 521/3343 17 (6-26) 17 (7-26)
All 2 774/5886 847/4432 31 (24-38) 28 (21-35)
* Direct effect estimates, ** Crude VE calculated by authors, NR not reported, ED emergency department, d days, AGE acute gastroenteritis, RVGE rotavirus
gastroenteritis, †GP consultations reported, paper also reported telephone triage and episodes (calls and visits within ten days), two cohorts were followed,
the 1st for two seasons and 2nd for one season
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were included. Some 22 estimates from 21 studies were
included, as Payne et al, 2013 had separate results for
RV1 and RV5 [28]. The funnel plot shows some asym-
metry, however this is not significant for Begg’s (p=0.06)
tests (Fig. 2). Therefore, we included all 21 studies in the
meta-analysis.
There was statistically significant heterogeneity (I2= 60.6,
p < 0.001) across all studies (Fig. 3). Therefore pooled
estimates of OR (0.18, 95% CI 0.14–0.23, 21 studies
[22 estimates], p<0.001) were calculated using a ran-
dom effects model. The pooled VE was therefore 82%
(95% CI 80–88%; 21 studies [22 estimates], p<0.001).
A stratified analysis by World Bank Country Classifi-
cations calculated pooled estimated ORs. Pooled VE was
lower in middle-income countries (74% VE; 95% CI 67-
80%; 9 studies, p<0.001) compared with high income
countries (89% VE; 95% CI 84-92%; 12 studies [13 esti-
mates], p<0.001). There was low to moderate
heterogeneity for middle (I2= 37.4%, p=0.120) and high
income countries (I2 = 40.8%, p=0.06). The study by
Cotes-Cantillo et al., 2014 was the only study to report a
negative vaccine effectiveness (-2 VE; 95% CI -182 to
63%) [29].
Pooled estimates for case-control studies in high in-
come settings (89% VE; 95% CI 84-92%; 12 studies
[13 estimates]) were comparable to the three
unpooled cohort study estimates. All cohort studies
were conducted in high income settings. One study
reported an adjusted VE estimate of 87% (95% CI 80-
92%) and other two studies stated unadjusted
Table 3 Quality of observational studies included in the review of rotavirus vaccine effectiveness. Using the Newcastle-Ottawa Scale
Study No. Study Country Study design Selection Comparability Outcome / exposure Overall Bias
1 Bellido-Blasco et al. 2012 [22] Spain Case-control 3 2 3 8 Low
2 Braeckman et al. 2012 [32] Belgium Case-control 3 2 3 8 Low
3 Carvalho-Costa et al. 2009 [25] Brazil Case-control 2 0 1 3 High
4 Castilla et al. 2012 [31] Spain Case-control 3 2 3 8 Low
5 Correia et al. 2010 [35] Brazil Case-control 3 1 3 8 Moderate
6 Cortese et al., 2011 [36] USA Case-control 3 2 3 8 Low
7 Cortese et al. 2013 [37] USA Case-control 3 2 3 8 Low
8 Cotes-Cantillo et al. 2014 [29] Colombia Case-control 3 2 3 8 Low
9 de Palma et al. 2010 [38] El Salvador Case-control 3 2 3 8 Low
10 Desai et al. 2010 [39] USA Case-control 3 2 2 7 Low
11 Donauer et al. 2013 [45] USA Case-control 2 2 2 6 Low
12 Guh et al. 2011 [40] USA Case-control 4 1 3 9 Moderate
13 Ichihara et al. 2014 [41] Brazil Case-control 3 2 2 7 Moderate
14 Justino et al. 2011 [33] Brazil Case-control 4 2 3 9 Low
15 Martinon-Torres et al. 2011 [24] Spain Case-control 4 0 2 6 High
16 Mast et al. 2011 [16] Nicaragua Case-control 3 2 1 7 Moderate
17 Muhsen et al. 2010 [42] Israel Case-control 3 2 1 6 Moderate
18 Patel et al. 2009 [26] Nicaragua Case-control 4 2 3 9 Low
19 Patel et al. 2012 [27] Nicaragua Case-control 4 2 2 8 Low
20 Patel et al. 2013 [43] Bolivia Case-control 3 2 3 8 Low
21 Payne et al. 2013 [28] USA Case-control 3 2 2 7 Low
22 Snelling et al. 2009 [44] Australia Case-control 3 2 3 8 Low
23 Staat et al. 2011 [34] USA Case-control 3 2 2 7 Low
24 Eberly et al. 2011 [23] USA Cohort 3 0 3 6 High
25 Fontes-Vieira et al. 2011 [17] Brazil Cohort 3 0 2 5 High
26 Muhsen et al. 2011 [18] Israel Cohort 3 1 3 7 Moderate
27 Nolan et al. 2012 [19] USA Cohort 4 2 3 9 Low
28 Panozzo et al. 2014 [30] USA Cohort 4 2 3 9 Low
29 Wang et al. 2010 [20] USA Cohort 4 1 3 8 Moderate
30 Wang et al. 2013 [21] USA Cohort 4 1 3 8 Moderate
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estimates of 100% (95% CI 87-100%), and 90% (95%
CI 82-95%) [20, 23, 30].
Sensitivity analysis
We identified the possibility of study bias using the
Newcastle-Ottawa Scale. The pooled OR for studies with
a low risk of bias was 0.18 (95% CI 0.13-0.25; 13 studies
[14 estimates], p<0.001), suggesting that any bias in
these studies may have been minimal. The correspond-
ing pooled estimates by World Bank classification did
not change substantially. When studies from countries
with state-based or private rotavirus vaccine provision
(Castilla et al 2012, Martinon-Torres, 2011 and Muhsen
et al., 2010) were dropped from the meta-analysis the
pooled OR remained similar (0.19 OR; 95% CI 0.14-0.25;
18 studies [19 estimates], p<0.001) [24, 31, 42].
To further investigate the potential for publication
bias, specifically that the effect of industry funding, we
excluded 4 studies which had measured RVGE hospitali-
sations but were funded by industry [16, 32–34]. Overall
pooled ORs remained comparable (0.19 OR; 95% CI
0.14-0.26 ; 17 studies [18 estimates], p<0.001). We also
established that including an estimate from a study
which measured vaccine effectiveness against severe
disease (Vesikari score ≥11), did not cause an overesti-
mation of the pooled estimate [16].
Subgroup analyses
Age Because the age groups included in studies were
varied we grouped ages in to the following groups to as-
sess VE by crude age groups: <1 year, <2 years, >1 year
and 1-2 years of age. In middle-income countries there
was some variation in pooled estimates by age group but
confidence intervals overlapped between estimates
(Fig. 4a). Here estimates should be interpreted with
caution as there was only 1 study in each of the 1-2
year and <2 year groups. Additionally, the VE esti-
mate for children aged >12 months from the 2014
study by Cotes-Cantillo stood out as being heteroge-
neous. As the authors note this is likely to be due to
the low sample size in this group and potentially due to
a variation in strain dominance by age [29]. Estimates
were very similar across age ranges in high-income
countries (Fig. 4b).
Full v partial vaccine dose To determine the impact of
the number of vaccine doses on vaccine effectiveness we
compared studies which reported full dose vaccination
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Hungerford et al. BMC Infectious Diseases  (2017) 17:569 Page 11 of 19
with first dose vaccination for RV1 and RV5 vaccine ef-
fectiveness estimates. There were 21 studies which either
reported full or partial vaccination giving 32 estimates
(13 partial schedule; 19 full vaccine schedule). Pooled
vaccine effectiveness for full dose (81% VE; 95% CI 75-
86%, p<0.001) was higher than for partial dose (62% VE;
95% CI 55-69%, p<0.001). However, there was moderate
to high heterogeneity for studies reporting estimates for
full dose (I2= 60.2%, p<0.001). When stratified by World
Bank classification, this difference was most pronounced
in middle income countries, where pooled vaccine ef-
fectiveness for full dose was 74% (95% CI 67-80%,
p<0.001) and 57% (95% CI 47-66%, p<0.001) for partial
dose (Fig. 5a). Wider confidence intervals were reported
in studies reporting full vaccination, likely due to smaller
available sample sizes. In high income countries VE for
partial vaccine dose was 72% (95% CI 60-80%, p<0.001)
compared to 87% (95% CI 81-91%, p<0.001) for full dose
(Fig. 5b).
RV1 and RV5 vaccine effectiveness Pooled VE for RV1
and RV5 stratified by World Bank country classification
showed that RV5 has slightly higher VE point estimates
in both high and middle income countries but this dif-
ference was not significant. RV1 is the predominant vac-
cine used in studies from middle income countries
included in the meta-analysis (7/10). In high income
countries three studies reported VE for RV1, six for RV5
and four RV1 and RV5 combined.
Meta-analysis of vaccine effectiveness against emergency
department attendances for RVGE
There were 4 estimates from three studies that included
measure of VE for ED attendances for RVGE [28, 29, 34].
Three estimates were from high income countries and
one from middle-income. Publication bias was not
assessed as there were inadequate numbers of studies to
properly assess via a Begg’s. Heterogeneity was high for
these studies (I2=78.7%, p<0.001). Random effects meta-
analysis gave a pooled OR of 0.26 (95% CI 0.12-0.57,
p=0.001), indicating a significant effect of vaccination
against ED attendances for RVGE (Fig. 6). Analysis strati-
fied by World Bank country classifications showed signifi-
cant VE of 81% (95% CI 75-86%, p<0.001) for studies from
NOTE: Weights are from random effects analysis
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Fig. 4 Vaccine effectiveness against hospitalisation or hospitalisation and emergency department attendance for laboratory confirmed RVGE
comparing partial age groups a middle income countries, b high income countries. (only adjusted effect estimates included)
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Fig. 5 Vaccine effectiveness against hospitalisation or hospitalisation and emergency department attendance for laboratory confirmed RVGE
comparing partial dose to full dose a middle income countries, b high income countries (only adjusted effect estimates included)
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high income countries. There was only one study from
middle income countries with a VE of 16% (95% CI -79%
to 61%, p=0.651).
Meta-analysis of vaccine effectiveness against community
consultations for AGE
A single study reported full dose vaccine effectiveness
against community consultations for laboratory con-
firmed RVGE, reporting a high unadjusted VE estimate
of 96% (95% CI 76-100%) [20, 21]. However, four cohort
studies included estimates of vaccine effectiveness for
community consultations for AGE [17–21]. Three stud-
ies were from high income countries and one from
middle-income. Only two out of the four studies re-
ported adjusted estimates. The study by Nolan et al.,
2012 only reported an adjusted VE for 1 or more doses
[19]. We therefore could only include three cohort stud-
ies which report unadjusted VE in the meta-analysis.
Publication bias was not assessed as there were inad-
equate numbers of studies to properly assess via a Begg’s
test. Heterogeneity was very high for these studies
(I2=97.9%, p<0.001). Random effects meta-analysis gave
a pooled RR of 0.74 (95% CI 0.52-1.06, p=0.10),
indicating a non-significant effect of vaccination against
community consultations for AGE (Fig. 7). However,
analysis stratified by World Bank country classifications
showed significant VE of 40% (95% CI 13-58%, p=0.008)
for studies from high income countries. There was only
one study from middle income countries with a VE of
-24% (95% -67% to 8%, p=0.157), this study was assessed
as having a high risk of bias as crude VE was calculated
by the authors and children in the vaccinated cohort
were significantly younger than the unvaccinated cohort.
Discussion
The pooled data from case-control studies indicates that
RV vaccination is highly effective for preventing hospita-
lisations and / or ED attendances for laboratory con-
firmed rotavirus, as VE was 89% (95% CI 84-92) for high
income countries and 74% (95% CI 67-80) for middle in-
come countries. This finding is further supported by
comparable estimates from the unpooled cohort studies.
Most studies reporting VE for community consultations
could not identify the causative organism and therefore
reported a much lower effectiveness against community
consultations for AGE (26% VE; 95% CI -6 to 48%).
NOTE: Weights are from random effects analysis
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However, like VE against RVGE hospitalisations and ED
attendances, the pooled VE for community consultations
for AGE was significant in high income countries (40%
VE; 95% CI 13-58%). This study was also able to show
that studies from countries with similar economic classi-
fication demonstrate similar effectiveness and that effect-
iveness was lower in middle income countries compared
with high income countries. Vaccine effectiveness
against RVGE hospitalisations in high income countries
(89% VE; 95% CI 84-92%) was consistent with but at the
upper limit of that reported in reported in a Cochrane
Review of RCTs; 85% (95% CI 80-88%) for RV1 and 82%
(95% CI 50-93%) for RV5 for preventing severe rotavirus
diarrhoea in children up to two years of age [6]. Differ-
ing study definitions of severity and age maybe respon-
sible for the slight difference between pooled estimates.
Additionally, pooled VE estimates from meta-analysis
for RVGE hospitalisations in middle income countries
(Brazil, Colombia, Nicaragua and Bolivia) were signifi-
cantly lower than high-income countries, again consist-
ent with estimates from efficacy studies [6, 48].
Our systematic review found substantial differences in
the quality and design of studies and considerable het-
erogeneity. However, there was no evidence of publica-
tion bias. Heterogeneity was dealt with by stratifying the
analysis by World Bank income classification when
heterogeneity was low to moderate and by using sen-
sitivity analysis to identify factors which may have
caused bias in the overall estimate. We conclude that
the best pooled estimates are provided by stratifying
by World Bank country classification. Sensitivity
analyses for RVGE hospitalisations and or ED atten-
dances did not identify any substantial effects result-
ing from differences in study quality. Exclusion of
studies from countries with only state based or pri-
vate provision of RV vaccination made little difference
to the overall effect estimates.
Sub-analyses by vaccine dose identified that 1 dose
of RV vaccine conferred a lower overall VE estimate
than full course dose, particularly in middle income
countries, indicating that there is a clear benefit for
children completing the full schedule. Wider confi-
dence intervals were seen for partial dose estimates
due to smaller available sample sizes which are likely
a result of the majority of children completing recom-
mended schedules.
It was difficult to assess VE by age as the different
studies reported VE for different age groups and there-
fore finding standard categorisations for age was prob-
lematic. Pooled VE estimates in children aged >1 year of
age in middle income countries were lower than for that
for infants <1 year of age. This could be due to the
higher relative disease burden in infants, a consequence
of acquiring natural immunity with age, independent of
vaccination [49]. Nonetheless, classifications used here
showed no significant differences between age groups in
both high and middle income countries, suggesting that
the RV vaccination is highly effective against RVGE hos-
pitalisation regardless of age. Interestingly, one study
from Colombia reported high VE in the <1 year olds
(84.4% VE; 95% CI 23-97%) but negative VE in >1 year
olds (-79% VE; 95% CI -556 to 51%), the authors
NOTE: Weights are from random effects analysis
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indicated that this could be because of a low sample size
in the older group and a change in the predominant
rotavirus strains circulating in Colombia during the
study to heterotypic non-vaccine strains [29].
Additionally, whilst prior to vaccination the predomin-
ant strain type in many high income countries was G1P
[8, 50] in lower and middle income countries there is
often greater strain diversity and concurrent circulation
of several strains simultaneously [1, 50]. It is possible
that the frequency of more strains that heteroptypic to
vaccine types may contribute to the lower effectiveness
of the vaccine in middle income countries. However,
there are likely to be inherent immununological and epi-
demiological factors at play [51].
Using meta-analysis to review VE against community
consultations for AGE is particularly important in high in-
come countries where the majority of the healthcare bur-
den from rotavirus infection is in community healthcare
settings. For instance in the UK rotavirus was deemed to
be responsible for approximately 800 000 general practice
consultations per year prior to vaccine introduction [4].
Pooled estimates presented here show a considerably
lower vaccine effectiveness against AGE community con-
sultations compared with RVGE hospitalisations in high
income countries. Since only one study is available for
middle income countries, evaluation of the effectiveness
of vaccination against AGE community consultations in
this setting is difficult, particularly because this study had
high risk of bias predominantly due to significant differ-
ences in age of the vaccinated and unvaccinated cohorts.
Whereas clinical trials have suggested lower efficacy
against milder disease [48, 52], a single study here re-
ported VE against laboratory confirmed RVGE commu-
nity consultations on par with VE against RVGE
hospitalisations [20, 21]. Whilst there was no-indicator
of disease severity in the study, the healthcare setting
suggests milder disease. Therefore there is a need for
more robustly designed studies in middle income set-
tings and high income countries in order to properly as-
sess RV vaccine effectiveness against milder disease
resulting in community consultations for RVGE.
Studies reviewed here represent countries with a World
Bank country classification of high or middle income, and
clearly show lower VE in middle income countries. How-
ever, the burden of disease is likely to be greater in middle
income countries representing a superior population
greater potential benefit of vaccination in these settings. At
time of review no studies could be included from low in-
come settings However, findings from a recent study in
Malawi suggest a VE of 64% (95% CI 24–83), similar to that
reported in middle income countries [53]. Future reviews
will be required to capture studies from these settings.
As these studies were conducted in the “real world”
with population level vaccine introduction the VE
estimates are likely to include both the direct effect and
any herd protective effect of population vaccination.
This could be particularly significant in cohort studies
with high population vaccine uptake. Indeed only one
study attempted to separate the herd protection and direct
effect from the overall effect of vaccination, estimating a
substantial increase in indirect effect of vaccination as
cohort vaccine uptake increased over time [30]. More
evidence of the indirect effect of vaccination is therefore
required through subsequent cohort studies.
We searched three widely used databases—PubMed,
Web of Science, and Academic Search Premier —as well
as grey literature using a pre-specified, systematic search
protocol. We were able to quality assess the studies
included using an established critically appraised tool
specifically for use with non-randomised studies in meta-
analysis, allowing a good understanding of a studies validity
importantly with reference to RCT as a gold standard. The
majority of studies were assessed as being at low or moder-
ate risk of bias strengthening the meta-analysis for RVGE
hospitalisation. However, our assessment of study bias used
one specific tool, the Newcastle-Ottawa Scale, with some
author defined criteria, therefore it is possible that another
bias assessment tool and criteria would identify different
risk of bias. Furthermore, variations in study outcome defi-
nitions and statistical methods could have introduced error
into some of our meta-analyses. For instance, heterogeneity
was moderate to high in some of the meta-analyses, par-
ticularly those that examined community consultations; this
could be related to varying definitions of a community
consultation.
Conclusions
This review and meta-analysis has enabled the system-
atic production of pooled VE estimates for rotavirus vac-
cination globally from the literature. We conclude that
RV vaccines represent a highly effective preventive
measure against severe rotavirus disease, with “real
world” vaccine effectiveness estimates as high as efficacy
measures from RCTs. There is sufficient evidence to
promote the continued roll out of both RV vaccines in
both high and middle income settings. The modest ben-
efits from vaccination against community consultations
for RVGE represent information which can be used in
appropriate cost-effectiveness studies, which may pro-
vide better understanding of the value of reducing mild
to moderate disease through vaccination.
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